EP0607275A1 - Treating ophthalmic fibrosis using interferon-alpha - Google Patents

Treating ophthalmic fibrosis using interferon-alpha

Info

Publication number
EP0607275A1
EP0607275A1 EP92921557A EP92921557A EP0607275A1 EP 0607275 A1 EP0607275 A1 EP 0607275A1 EP 92921557 A EP92921557 A EP 92921557A EP 92921557 A EP92921557 A EP 92921557A EP 0607275 A1 EP0607275 A1 EP 0607275A1
Authority
EP
European Patent Office
Prior art keywords
interferon
patient
treatment
diluent
excipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92921557A
Other languages
German (de)
French (fr)
Other versions
EP0607275A4 (en
Inventor
Mark Cedric Gillies
Nigel Morlet
Marc George Sarossy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0607275A1 publication Critical patent/EP0607275A1/en
Publication of EP0607275A4 publication Critical patent/EP0607275A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Definitions

  • the present invention relates to the use of topical interferon- ⁇ for the treatment of various forms of fibrosis in and around the eye arising from various ophthalmic diseases
  • the invention relates to alleviation of corneal scarring after laser photoablative refractive keratectomy (PRK). It also relates to the alleviation of
  • Interferon- ⁇ may also be used to coat the lens implant prior to or during implantation. It
  • 10 may also possibly be injected into the eye during eye surgery for inhibiting posterior capsule opacification after cataract surgery and in addition may be injected into the vitreous body to prevent retinal fibrosis and proliferative vitreo-retinopathy, and injected subconjunctivally to inhibit fibrosis and scarring following glaucoma filtration surgery.
  • Interferons are a heterogeneous group of proteins that can inhibit many aspects of the fibrotic response. Originally identified by their well known ability to interfere with the production of viral RNA and protein, they also exert anticellular activities generally considered to be inhibitory, which maybe due to their ability to inhibit the c-myc proto- oncogene.
  • Type I interferon viral interferon, interferon- ⁇ and - ⁇
  • type LI immune interferon, interferon- ⁇
  • ⁇ -interferon is secreted by leukocytes, ⁇ - by fibroblasts and ⁇ - by stimulated lymphocytes. Interferons, particularly interferon- ⁇ , have been successfully used in humans for twenty years for the treatment of systemic malignancy.
  • Fibroblasts are stimulated to produce interferons by many cytokines that mediate wound healing, such as interieukin-l-(LL-l), platelet derived growth factor (PDGF) and tumour necrosis factor (TNF). Interferons inhibit fibroblast chemotaxis and proliferation as well as collagen production, the latter synergistically with TNF- ⁇ . Intraperitoneally implanted foreign bodies in mice suffered less encapsulation in the presence of interferon- ⁇ , the capsules having a reduced collagen content.
  • cytokines that mediate wound healing
  • PDGF platelet derived growth factor
  • TNF tumour necrosis factor
  • Fibroblast glycosaminoglycan production is inhibited by interferon- ⁇ , while collagenase production is increased. This deactivation of activated fibroblasts can persist for a long time after a brief exposure to interferon. Of the different types of interferon, the ⁇ - and ⁇ - subclasses exhibit a broader antifibrotic spectrum.
  • interferon- ⁇ inhibits foetal calf serum and platelet derived growth factor induced proliferation of human tenon's capsule fibroblasts in vitro. They suggest that interferons may prove to be of benefit in the treatment of fibrosis following PRK in particular, and of ocular fibrosis in general.
  • a method for the treatment of corneal scarring in a patient requiring such treatment comprising administering to the cornea of said patient an effective amount of interferon- ⁇ or a pharmaceutical composition for the treatment of corneal scarring in a patient comprising ⁇ nterferon- ⁇ together with a pharmaceutically acceptable carrier, diluent and/or excipient.
  • a method for inhibiting opacification of the posterior capsule after extracapsular cataract surgery comprising administering to the lens capsule of said patient an effective amount of interferon- ⁇ or a pharmaceutical composition for this method comprising interferon- ⁇ together with a pharmaceutically acceptable carrier, diluent and/or excipient.
  • a method for inhibiting wound fibrosis and scarring after glaucoma filtration surgery, in a patient requiring such treatment comprising administering to the subconjunctival space of said patient an effective amount of interferon- ⁇ or a pharmaceutical composition for this method comprising interferon- ⁇ together with a pharmaceutically acceptable carrier, diluent and/or excipient.
  • ⁇ occlusion in a patient requiring such treatment, comprising administering to the vitreous body or retina of said patient an effective amount of interferon- ⁇ or a pharmaceutical composition for this method comprising interferon- ⁇ together with a pharmaceutically
  • Interferon- ⁇ 2 A, interferon- ⁇ 2B or interferon- ⁇ 2C or any other type of interferon- ⁇ may be used in this invention.
  • the invention also provides novel protein formulations in which the carrier or diluent is a bioerodable polymer, e.g. a polymer ester (polyanhydrine), which may be a 15 copolymer of sebacic acid and bis paracarboxyphenoxybutane; or a poly(ortho) ester.
  • a bioerodable polymer e.g. a polymer ester (polyanhydrine), which may be a 15 copolymer of sebacic acid and bis paracarboxyphenoxybutane; or a poly(ortho) ester.
  • the method of this, invention inhibits the scarring response following a variety of corneal procedures such as photoablative refractive keratectomy; lamellar keratoplasty; lamellar keratectomy; epikeratoplasty; removal of pterygium and keratomileusis.
  • the patient on whom the methods of this invention are used is a human. 20 However, the methods would also be able to be used on other mammals.
  • the methods of this invention may also inhibit scarring after chemical damage to conjunctiva and comea and may also prevent scarring in pathological conditions such as ocular pemphigoid and StevensJohnson's syndrome, Simplex & Zoster keratitis. It may also inhibit fibrosis in thyroid eye disease, orbital psuedo-tumour and ocular myositis. 25 Preparation of topical composition drops are made up from Intron A powder
  • Intron A Formulation of Intron A is as follows: ⁇ - 2b interferon solution Dibasic sodium phosphate, anhydrous, USP 30 Monosodium phosphate, monohydrate, USP
  • Glycine ph. eur. Human albumin solution, ph. eur. ⁇ Water for injection, ph. eur.
  • Drops base may be hypromellose or polyvinyl alcohol for dilution to 10 6 IU/mL.
  • t 35 The composition of the present invention may be administered topically as a solution, ointment, or within a collagen shield or similar dissolving corneal contact protective dressing containing conventional, non-toxic, pharmaceutically acceptable carriers, diluents and/or excipients as desired, or by direct injection.
  • the dosage range of interferon- ⁇ may be between about 50,000 and 50 x 10 6 IU and may be between about 1 x 10 6 to 20 x 10 6 IU/mL. Preferably the dosage is between about lxlO 6 and about lOxlO 6 IU/mL.
  • the interferon- ⁇ may be administered in 50 ⁇ L drops, four times a day for six weeks; or preferably two times a day for one week. Interferon- ⁇ may also be administered two times a day for three days or one drop hourly for three days. This dosage range is applicable to the first, second and third embodiments of the invention.
  • the interferon- ⁇ is given by intravitreal injection within the range of 50,000 to 5.0 x 10 6 IU/O.lmL.
  • compositions of this invention may also contain a slow release polymer.
  • the pharmaceutically acceptable carriers, diluents and/or excipients are those well known in the art of ophthalmic surgery and comprise the following: hydroxyethyl cellulose, hypromellose, polyvinyl alcohol, gelatin, polyquad, dextran, castor oil or other vegetable oil e.g. sesame, inert soft white paraffin, liquid paraffin, anhydrous lanolin, sodium hyalusonate, methyl cellulose, potassium sorbate, polysorbate; or sodium chloride, sodium phosphate, buffers hydrochloric acid bicarbonate, Na citrate (citric acid) boric acid in purified water.
  • They may also be biodegradable polymer esters (polyanhydrines) e.g. sebacic acid and bis paracarboxyphenoxybutane, which are employed in the novel formulations of the invention.
  • compositions may also contain preservatives and antiseptics such as: thiomersal, phenyl mercuric acetate, benzylalkonium chloride, disodium edetate, sodium metabisulfite, polymercuric nitrate, chlorobutol, hyloxapol, povidone, propyl hydroxy benzoate, methyl hydroxy benzoate.
  • preservatives and antiseptics such as: thiomersal, phenyl mercuric acetate, benzylalkonium chloride, disodium edetate, sodium metabisulfite, polymercuric nitrate, chlorobutol, hyloxapol, povidone, propyl hydroxy benzoate, methyl hydroxy benzoate.
  • composition of this invention be applied to the cornea immediately following photoablative refractive keratectomy.
  • the interferon is applied as a drop, it is preferably to treat the eye thus, four to eight times a day for up to about 6 weeks.
  • the corneal response may be modified by the pre-treatment with interferon ⁇ drops before PRK. It may also be modified by pre-treatment with steroid drops.
  • the interferon- ⁇ may be prepared from natural sources or may be prepared by recombinant DNA techniques. All of these techniques would be well known to one skilled in this art.
  • Example 1 Preparation of interferon ⁇ -2B topical composition
  • Preparation of topical composition drops are made up from Intron A powder (Schering-Plough) to a solution of 1 x 10 6 IU/mL.
  • Formulation of Intron A is as follows: ⁇ -2b interferon solution Dibasic sodium phosphate, anhydrous, USP
  • the drops base is hypromellose or polyvinyl alcohol for dilution to 10 6 IU/mL.
  • Example 2 The composition of this invention is applied to the cornea immediately following photoablative refractive keratectomy, As a drop, ointment or collagen shield etc. Where the interferon is applied as a drop, it is preferable to treat the eye thus, four times a day for up to about 6 weeks.
  • the corneal response may be modified by the pre-treatment with interferon- ⁇ -2b drops before PRK. It may also be modified by pre-treatment with steroid drops.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne l'utilisation de l'interféron-alpha local dans le traitement de différentes formes de fibroses, à l'intérieur et autour de l'oeil résultant de différentes maladies et opérations ophtalmiques. De manière spécifique, l'invention concerne l'atténuation des cicatrices de la cornée après la kératectomie réfractive photo-ablative par laser (PRK). Elle concerne également l'atténuation de l'opacification capsulaire (cristallin) postérieure après l'opération de la cataracte extacapsulaire avec un implant de cristallin; l'atténuation des cicatrices suivant l'opération de la filtration du glaucome. L'interféron-alpha peut aussi être utilisé pour recouvrir le cristallin à implanter avant ou pendant l'implantation. Il peut aussi être injecté dans l'oeil durant l'opération de l'oeil pour éliminer l'opacification postérieure de la capsule après l'opération de la cataracte et de plus, il peut être injecté dans l'humeur vitrée, pour éviter la fibrose de la rétine et une rétinopathie du corps vitré proliférative, et injecté sous-conjonctivalement pour éviter les fibroses et les cicatrices suivant l'opération de filtration du glaucome.The present invention relates to the use of local interferon-alpha in the treatment of different forms of fibrosis, in and around the eye resulting from different diseases and ophthalmic operations. Specifically, the invention relates to the attenuation of scarring of the cornea after refractive photo-ablative keratectomy by laser (PRK). It also relates to the attenuation of the posterior capsular (lens) opacification after the operation of the extacapsular cataract with a lens implant; the reduction of scars following the glaucoma filtration operation. Interferon-alpha can also be used to cover the lens to be implanted before or during implantation. It can also be injected into the eye during the operation of the eye to eliminate the posterior clouding of the capsule after the cataract operation and moreover, it can be injected into the vitreous humor, to avoid retinal fibrosis and proliferative vitreous retinopathy, and injected subconjunctivally to avoid fibrosis and scarring following the glaucoma filtration operation.

Description

TREATING OPHTHALMIC FIBROSIS USING INTERFERON-ALPHA
Technical Field
The present invention relates to the use of topical interferon-α for the treatment of various forms of fibrosis in and around the eye arising from various ophthalmic diseases
^ 5 and procedures. Specifically the invention relates to alleviation of corneal scarring after laser photoablative refractive keratectomy (PRK). It also relates to the alleviation of
'" posterior (lens) capsular opacification after extracapsular cataract surgery with lens implant; the alleviation of wound scarring following glaucoma filtration surgery.
Interferon-α may also be used to coat the lens implant prior to or during implantation. It
10 may also possibly be injected into the eye during eye surgery for inhibiting posterior capsule opacification after cataract surgery and in addition may be injected into the vitreous body to prevent retinal fibrosis and proliferative vitreo-retinopathy, and injected subconjunctivally to inhibit fibrosis and scarring following glaucoma filtration surgery.
Background Art 15 In the field of ophthalmic surgery, it is known to use excimer laser photoablative refractive keratectomy to sculpt the cornea of the eye in order to relieve refractive errors (e.g. myopia) and a number of corneal conditions and diseases. Specifically, the 193nm argon fluoride excimer laser is able to discretely remove corneal tissue by photoablation without thermal damage to surrounding tissue. 20 Of major concern is the activation of the stro al keratocytes when a wound is made to the stroma. As is well known, the basic response of wounded tissue is to repair the defect and therefore the ophthalmic surgeon when using this technique is confronted with alteration to the biochemistry, morphologic features and tissue function unpredictability brought about by the wound itself and the healing phenomenon. 25 Therefore, even though excimer laser ablation of corneal tissue appears to be an efficient method of removing tissue with minimal damage to adjacent areas, nevertheless the healing process does not always lead to the preservation of transparent corneal tissue. Previous methods of overcoming this problem have been: application of topical steroids such as prednisolone, prednisolone acetate, prednisolone sodium phosphate, 30 fluoromethalone, fluoromethalone acetate, hydromesterone, dexamethasone, and dexamethasone alcohol. Other compounds tested have been idoxuridine, collagen cross- linkage inhibitors and mitomycin C. f It is an object of this invention to ameliorate the known disadvantages of present techniques when dealing with the wound repair mechanism following photoablative 35 refractive keratectomy.
Interferons are a heterogeneous group of proteins that can inhibit many aspects of the fibrotic response. Originally identified by their well known ability to interfere with the production of viral RNA and protein, they also exert anticellular activities generally considered to be inhibitory, which maybe due to their ability to inhibit the c-myc proto- oncogene. Type I interferon (viral interferon, interferon-α and -β) is produced in response to viral infection, and type LI (immune interferon, interferon-γ) in response to specific antigens or mitogens. Of the different classes, α-interferon is secreted by leukocytes, β- by fibroblasts and γ- by stimulated lymphocytes. Interferons, particularly interferon-α, have been successfully used in humans for twenty years for the treatment of systemic malignancy.
Considerable interest has recently been shown in the potential of interferon as a treatment for such fibrotic diseases as systemic sclerosis, pulmonary fibrosis and keloid. Fibroblasts are stimulated to produce interferons by many cytokines that mediate wound healing, such as interieukin-l-(LL-l), platelet derived growth factor (PDGF) and tumour necrosis factor (TNF). Interferons inhibit fibroblast chemotaxis and proliferation as well as collagen production, the latter synergistically with TNF-α. Intraperitoneally implanted foreign bodies in mice suffered less encapsulation in the presence of interferon-γ, the capsules having a reduced collagen content. Fibroblast glycosaminoglycan production is inhibited by interferon-α, while collagenase production is increased. This deactivation of activated fibroblasts can persist for a long time after a brief exposure to interferon. Of the different types of interferon, the α- and β- subclasses exhibit a broader antifibrotic spectrum.
The present inventors have recently demonstrated that interferon-α inhibits foetal calf serum and platelet derived growth factor induced proliferation of human tenon's capsule fibroblasts in vitro. They suggest that interferons may prove to be of benefit in the treatment of fibrosis following PRK in particular, and of ocular fibrosis in general.
Disclosure of the Invention According to a first form of this invention, there is provided a method for the treatment of corneal scarring in a patient requiring such treatment, comprising administering to the cornea of said patient an effective amount of interferon-α or a pharmaceutical composition for the treatment of corneal scarring in a patient comprising ϊnterferon-α together with a pharmaceutically acceptable carrier, diluent and/or excipient. According to a second form of this invention, there is provided a method for inhibiting opacification of the posterior capsule after extracapsular cataract surgery, in a patient requiring such treatment, comprising administering to the lens capsule of said patient an effective amount of interferon-α or a pharmaceutical composition for this method comprising interferon-α together with a pharmaceutically acceptable carrier, diluent and/or excipient.
According to a third form of this invention, there is provided a method for inhibiting wound fibrosis and scarring after glaucoma filtration surgery, in a patient requiring such treatment, comprising administering to the subconjunctival space of said patient an effective amount of interferon-α or a pharmaceutical composition for this method comprising interferon-α together with a pharmaceutically acceptable carrier, diluent and/or excipient.
According to a fourth form of this invention, there is provided a method for inhibiting formation of pre-retinal membranes and proliferative vitreo-retinopathy 5 following retinal detachment surgery and/or vitrectomy, following trauma, and as a result of retinal vascular disease (including diabetes, thalassaemia and retinal vein
^ occlusion) in a patient requiring such treatment, comprising administering to the vitreous body or retina of said patient an effective amount of interferon-α or a pharmaceutical composition for this method comprising interferon-α together with a pharmaceutically
10 acceptable carrier, diluent and/or excipient.
Interferon-α 2 A, interferon-α 2B or interferon-α 2C or any other type of interferon-α may be used in this invention.
The invention also provides novel protein formulations in which the carrier or diluent is a bioerodable polymer, e.g. a polymer ester (polyanhydrine), which may be a 15 copolymer of sebacic acid and bis paracarboxyphenoxybutane; or a poly(ortho) ester.
The method of this, invention inhibits the scarring response following a variety of corneal procedures such as photoablative refractive keratectomy; lamellar keratoplasty; lamellar keratectomy; epikeratoplasty; removal of pterygium and keratomileusis.
Typically, the patient on whom the methods of this invention are used is a human. 20 However, the methods would also be able to be used on other mammals.
The methods of this invention may also inhibit scarring after chemical damage to conjunctiva and comea and may also prevent scarring in pathological conditions such as ocular pemphigoid and StevensJohnson's syndrome, Simplex & Zoster keratitis. It may also inhibit fibrosis in thyroid eye disease, orbital psuedo-tumour and ocular myositis. 25 Preparation of topical composition drops are made up from Intron A powder
(Schering-Plough) or Roferon-A (Roche) to a solution of 1 x 106 IU/mL. Formulation of Intron A is as follows: α- 2b interferon solution Dibasic sodium phosphate, anhydrous, USP 30 Monosodium phosphate, monohydrate, USP
Glycine, ph. eur. Human albumin solution, ph. eur. ♦ Water for injection, ph. eur.
Drops base may be hypromellose or polyvinyl alcohol for dilution to 106 IU/mL. "t 35 The composition of the present invention may be administered topically as a solution, ointment, or within a collagen shield or similar dissolving corneal contact protective dressing containing conventional, non-toxic, pharmaceutically acceptable carriers, diluents and/or excipients as desired, or by direct injection.
The dosage range of interferon-α may be between about 50,000 and 50 x 106 IU and may be between about 1 x 106 to 20 x 106 IU/mL. Preferably the dosage is between about lxlO6 and about lOxlO6 IU/mL. The interferon-α may be administered in 50 μL drops, four times a day for six weeks; or preferably two times a day for one week. Interferon-α may also be administered two times a day for three days or one drop hourly for three days. This dosage range is applicable to the first, second and third embodiments of the invention.
When applied according to the fourth embodiment the interferon-α is given by intravitreal injection within the range of 50,000 to 5.0 x 106 IU/O.lmL.
The compositions of this invention may also contain a slow release polymer. The pharmaceutically acceptable carriers, diluents and/or excipients are those well known in the art of ophthalmic surgery and comprise the following: hydroxyethyl cellulose, hypromellose, polyvinyl alcohol, gelatin, polyquad, dextran, castor oil or other vegetable oil e.g. sesame, inert soft white paraffin, liquid paraffin, anhydrous lanolin, sodium hyalusonate, methyl cellulose, potassium sorbate, polysorbate; or sodium chloride, sodium phosphate, buffers hydrochloric acid bicarbonate, Na citrate (citric acid) boric acid in purified water. They may also be biodegradable polymer esters (polyanhydrines) e.g. sebacic acid and bis paracarboxyphenoxybutane, which are employed in the novel formulations of the invention.
The compositions may also contain preservatives and antiseptics such as: thiomersal, phenyl mercuric acetate, benzylalkonium chloride, disodium edetate, sodium metabisulfite, polymercuric nitrate, chlorobutol, hyloxapol, povidone, propyl hydroxy benzoate, methyl hydroxy benzoate.
It is preferable that the composition of this invention be applied to the cornea immediately following photoablative refractive keratectomy. As a drop, ointment or collagen shield etc. Where the interferon is applied as a drop, it is preferably to treat the eye thus, four to eight times a day for up to about 6 weeks.
The corneal response may be modified by the pre-treatment with interferon α drops before PRK. It may also be modified by pre-treatment with steroid drops.
The interferon-α may be prepared from natural sources or may be prepared by recombinant DNA techniques. All of these techniques would be well known to one skilled in this art.
Best Mode and Other Modes for Carrying Out the Invention An effective amount of interferon-α-2b to prevent corneal scarring after photoablative refractive keratectomy is administered topically to the cornea which has been subjected to this procedure.
The present invention will now be described with reference to the following examples which should not be construed as limiting on the scope thereof. Example 1 Preparation of interferon α-2B topical composition Preparation of topical composition drops are made up from Intron A powder (Schering-Plough) to a solution of 1 x 106 IU/mL. Formulation of Intron A is as follows: α-2b interferon solution Dibasic sodium phosphate, anhydrous, USP
Monosodium phosphate, monohydrate, USP Glycine, ph. eur. Human albumin solution, ph. eur.
Water for injection, ph. eur. The drops base is hypromellose or polyvinyl alcohol for dilution to 106 IU/mL.
Example 2 The composition of this invention is applied to the cornea immediately following photoablative refractive keratectomy, As a drop, ointment or collagen shield etc. Where the interferon is applied as a drop, it is preferable to treat the eye thus, four times a day for up to about 6 weeks.
The corneal response may be modified by the pre-treatment with interferon-α-2b drops before PRK. It may also be modified by pre-treatment with steroid drops. Industrial Applicability
It should be clear that the method of treatment of this invention will find wide use in the veterinary and medical fields.
The foregoing describes only some embodiments of the present invention and modifications obvious to those skilled in the art can be made thereto without departing from the scope of the invention.
References Gipson IK (1990) Archives of Opthalmology 108 1539. Cintron C (1990) Archives of Opthalmology 108 1540. Binder PS (1990) Archives of Opthalmology 108 1541.

Claims

Method of TreatmentClaims
1. Use of interferon-α for treating corneal scarring, for inhibiting opacification ofthe posterior capsule after extracapsular cataract surgery, for inhibiting wound fibrosis
5 and scarring after glaucoma filtration surgery, or for inhibiting formation of pre-retinal membranes and proliferative vitreo-retinopathy.
2. Use according to claim 1 wherein the dosage of interferon-α is between about
50,000 and 50 x 106 IU/mL.
3. Use according to claim 2 wherein the dosage unit is between about 1 x 106 to 10 20 x 106 IU/mL.
4. Use according to claim 3 wherein the dosage range is between about 1 x 106 and about 10 x 106 IU/mL.
5. Use according to any one of claims 1 to 4 wherein the interferon-α is interferon-α-2A. 5
6. Use according to any one of claims 1 to 4 wherein interferon-α is interferon- α-2B.
7. Use according to any one of claims 1 to 4 wherein interferon-α is interferon- α-2C.
8. A process for preparing a composition of interferon-α comprising 0 formulating interferon-α together with a pharmaceutically carrier, diluent and/or excipient.
9. The process of claim 8 wherein the carrier, diluent and/or excipient is a bioerodable polymer.
10. A process of claim 9 wherein the bioerodable polymer is a polymer ester 5 (polyanhydrine) or a poly(ortho) ester.
11. A process of claim 10 wherein the polyanhydrine is a copolymer of sebacic acid and bisparacarboxyphenoxybutane.
12. A method for the treatment of corneal scarring in a patient requiring such treatment, comprising administering to the cornea of said patient an effective amount of 0 interferon-α or a pharmaceutical composition for the treatment of corneal scarring in a patient comprising interferon-α together with a pharmaceutically acceptable carrier, diluent and/or excipient.
13. A method for inhibiting opacification of the posterior capsule after extracapsular cataract surgery, in a patient requiring such treatment, comprising administering to the lens capsule of said patient an effective amount of interferon-α or a pharmaceutical composition for this method comprising interferon-α together with a pharmaceutically acceptable carrier, diluent and/or excipient.
14. A method for inhibiting wound fibrosis and scarring after glaucoma filtration surgery, in a patient requiring such treatment, comprising administering to the subconjunctival space of said patient an effective amount of interferon-α or a pharmaceutical composition for this method comprising interferon-α together with a pharmaceutically acceptable carrier, diluent and/or excipient.
15. The method according to any one of claims 12 to 14 wherein the dosage of interferon-α range is between about 50,000 and 50 x 106 IU/mL.
16. The method according to claim 15 wherein the dosage unit is between about 1 x 106 to 20 x 106 IU/mL.
17. The method according to claim 16 wherein the dosage range is between about 1 x 106 and about 10 x 106 IU/mL.
18. The method according to any one of claims 14 to 17 wherein the interferon-α may be administered in about 50μL drops four times a day for six weeks.
19. The method according to claim 18 wherein the interferon-α may be administered two times a day for three days.
20. The method according to any one of claims 14 to 17 wherein the interferon-α is administered as one drop hourly for three days.
21. A method for inhibiting formation of pre-retinal membranes and proliferative vitreo-retinopathy following retinal detachment surgery and/or vitrectomy, following trauma, and as a result of retinal vascular disease (including diabetes, thalassaemia and retinal vein occlusion) in a patient requiring such treatment, comprising administering to the vitreous body or retina of said patient an effective amount of interferon-α or a pharmaceutical composition for this method comprising interferon-α together with a pharmaceutically acceptable carrier, diluent and/or excipient.
22. The method according to claim 21 wherein the interferon-α is given by intravitreal injection within the range of about 50,000 to 5.0 x 106 IU/O.lmL.
EP92921557A 1991-10-11 1992-10-12 Treating ophthalmic fibrosis using interferon-alpha. Withdrawn EP0607275A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPK886591 1991-10-11
AU8865/91 1991-10-11
AU9080/91 1991-10-22
AUPK908091 1991-10-22
PCT/AU1992/000541 WO1993006856A1 (en) 1991-10-11 1992-10-12 Treating ophthalmic fibrosis using interferon-alpha

Publications (2)

Publication Number Publication Date
EP0607275A1 true EP0607275A1 (en) 1994-07-27
EP0607275A4 EP0607275A4 (en) 1995-02-22

Family

ID=25644122

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92921557A Withdrawn EP0607275A4 (en) 1991-10-11 1992-10-12 Treating ophthalmic fibrosis using interferon-alpha.

Country Status (4)

Country Link
EP (1) EP0607275A4 (en)
JP (1) JPH07501320A (en)
CA (1) CA2120950A1 (en)
WO (1) WO1993006856A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029092A1 (en) * 1995-03-17 1996-09-26 Toray Industries, Inc. Corneal vascularization inhibitor
EP0797998A4 (en) * 1995-11-17 2003-01-15 Toray Industries Endothelial cell protective
CA2243161A1 (en) * 1996-11-22 1998-05-28 Toray Industries, Inc. Use of interferon-beta to treat retinal edema
WO1998029069A2 (en) * 1997-01-02 1998-07-09 Allergan Sales, Inc. Method for changing the refractive power of an eye
WO2006136116A1 (en) * 2005-06-24 2006-12-28 Centro De Ingenieria Genetica Y Biotecnologia Use of interferon-alpha in order to obtain a compound for the treatment of optical neuromyelitis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6391331A (en) * 1986-10-03 1988-04-22 Senjiyu Seiyaku Kk Ophthalmic aqueous composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0082481B2 (en) * 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
DE3603444A1 (en) * 1986-02-05 1987-08-06 Thomae Gmbh Dr K PHARMACEUTICAL PREPARATIONS FOR STABILIZING INTERFERON ALPHA
DE3628468A1 (en) * 1986-08-21 1988-03-03 Thomae Gmbh Dr K NEW APPLICATION FORM (ALPHA) INTERFERONE
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6391331A (en) * 1986-10-03 1988-04-22 Senjiyu Seiyaku Kk Ophthalmic aqueous composition

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIOLOGICAL ABSTRACTS, vol. 84, no. 10 1987, Philadelphia, PA, US; abstract no. 104066, IHKI KOHTAROH ET AL 'Toxicity of intravitreal interferon in combination with acyclovir after lensectomy and vitrectomy' page AB-1123 ; & FOLIA OPHTHALMOL. JPN, vol.38, no.2, 1987 pages 158 - 161 *
BIOLOGICAL ABSTRACTS, vol. 90, no. 7 1990, Philadelphia, PA, US; abstract no. 72950, C. D. INCORVAIA ET AL 'Alpha-interferon and acyclovir in the treatment of experimental herpetic keratitis' page AB-189 ; & BOLL. OCUL., vol.69, no.2, 1990 pages 217 - 226 *
BIOLOGICAL ABSTRACTS, vol. 91, no. 11 1991, Philadelphia, PA, US; abstract no. 116076, M. SALDUCCI ET AL 'Natural alpha interferon eye-drops for therapy of viral conjunctivitis and /or keratitis' page AB-208 ; & ANN. OTTALMOL. CLIN. OCUL., vol.116, no.1, 1990 pages 41 - 47 *
PATENT ABSTRACTS OF JAPAN vol. 12, no. 326 (C-525) (3173) 5 September 1988 & JP-A-63 091 331 (SENJIYU SEIYAKU K.K.) 22 April 1988 *
See also references of WO9306856A1 *

Also Published As

Publication number Publication date
WO1993006856A1 (en) 1993-04-15
EP0607275A4 (en) 1995-02-22
JPH07501320A (en) 1995-02-09
CA2120950A1 (en) 1993-04-15

Similar Documents

Publication Publication Date Title
US5811446A (en) Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
Shields et al. Clinical and histopathologic observations concerning hypotony after trabeculectomy with adjunctive mitomycin C
Fujitani et al. Corneoscleral ulceration and corneal perforation after pterygium excision and topical mitomycin C therapy
JPH10158188A (en) Composition for treating cornea
ZA200503975B (en) Use of rimexolone in the treatment of dry eye
Kenyon Decision-making in the therapy of external eye disease: noninfected corneal ulcers
CA2138644A1 (en) Method of treating ophthalmic disorders using tgf-.beta.
Phinney et al. Corneal edema related to accidental Hibiclens exposure
US7977385B2 (en) Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
AU2009201897B2 (en) Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
AU752950B2 (en) Remedies for corneal epithelium disturbance
Gelender Bacterial endophthalmitis following cutting of sutures after cataract surgery
EP0607275A1 (en) Treating ophthalmic fibrosis using interferon-alpha
WO2018066963A1 (en) Pharmaceutical composition for treating corneal injury containing 8-oxo-deoxyguanosine or pharmaceutically acceptable salt thereof as active ingredient
US5863530A (en) Treating ophthalmic fibrosis using interferon-α
US9011845B2 (en) Methods for treatment of inflammatory and infectious viral diseases
JPH06271478A (en) Agent for treating dry eye
AU2774892A (en) Treating ophthalmic fibrosis using interferon-alpha
EP3338792A1 (en) Corneal damage prevention/treatment composition comprising thymosin beta 4 and citric acid as active ingredients
EP0080032A2 (en) Pharmaceutical preparation for treating herpetic lesions
Holland et al. Subepithelial infiltrates in Acanthamoeba keratitis
US8877183B2 (en) Methods for treatment of ocular diseases
Gillies et al. Glaucoma filtering surgery with interferon-α-2b
US5721206A (en) Pharmaceutical composition for use as a retinal pigment epithelial cell growth agent
Genvert et al. Treatment of marginal corneal ulcers with cryotherapy and conjunctival recession or resection

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940427

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19990528

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19991208